Opportunities Outside of Diabetes and Obesity Additional Indications for Exploration Additional Indications for Exploration As new companies look to enter the incretin mimetic space, and existing players seek to expand their portfolios, its increasingly important to look beyond diabetes and obesity
A substance or method will be considered for inclusion on the WADA Prohibited List by the WADA List Expert Advisory Group if the substance or method meets two of the following three criteria: It has the potential to enhance or enhances sport performance
USA 122 , e2424470122 (2024)
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
It assists other antioxidants
facts-about-indoor-tanning [32] Tuunainen A, Kripke DF, Endo T
